{'fraction_non_alphanumeric': 0.02034428794992175, 'fraction_numerical': 0.0, 'mean_word_length': 5.881720430107527, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Addressable enzymes as protein therapeutics

Adzymes are ‘addressable enzymes’ containing an address domain that binds to a target molecule, and a catalytic domain that degrades or modifies the target. Adzymes are principally designed for the catalytic degradation of bioactive polypeptides, for example, inflammatory mediators. A well-characterised, functional example of an adzyme contains human mesotrypsin as the catalytic domain in fusion with a TNF-α binding protein. Adzymes represent a new generation of protein therapeutics with significant untapped potential, which warrants additional studies to demonstrate in vivo feasibility.